Newly Developed Drugs for Alzheimer's Disease in Relation to Energy Metabolism, Cholinergic and Monoaminergic Neurotransmission
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F62690094%3A18470%2F18%3A50014257" target="_blank" >RIV/62690094:18470/18:50014257 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11110/18:10361783 RIV/60162694:G44__/18:43889434 RIV/00023752:_____/18:43919300 RIV/00179906:_____/18:10361783
Result on the web
<a href="https://www.sciencedirect.com/science/article/pii/S0306452217304396?via%3Dihub" target="_blank" >https://www.sciencedirect.com/science/article/pii/S0306452217304396?via%3Dihub</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.neuroscience.2017.06.034" target="_blank" >10.1016/j.neuroscience.2017.06.034</a>
Alternative languages
Result language
angličtina
Original language name
Newly Developed Drugs for Alzheimer's Disease in Relation to Energy Metabolism, Cholinergic and Monoaminergic Neurotransmission
Original language description
Current options for Alzheimer's disease (AD) treatment are based on administration of cholinesterase inhibitors (donepezil, rivastigmine, galantamine) and/or memantine, acting as an N-methyl-D-aspartate (NMDA). Therapeutic approaches vary and include novel cholinesterase inhibitors, modulators of NMDA receptors, monoamine oxidase (MAO) inhibitors, immunotherapeutics, modulators of mitochondrial permeability transition pores (mPTP), amyloid-beta binding alcohol dehydrogenase (ABAD) modulators, antioxidant agents, etc. The novel trends of AD therapy are focused on multiple targeted ligands, where mostly ChE inhibition is combined with additional biological properties, positively affecting neuronal energy metabolism as well as mitochondrial functions, and possessing antioxidant properties. The present review summarizes newly developed drugs targeting cholinesterase and MAO, as well as drugs affecting mitochondrial functions.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30107 - Medicinal chemistry
Result continuities
Project
Result was created during the realization of more than one project. More information in the Projects tab.
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2018
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Neuroscience
ISSN
0306-4522
e-ISSN
—
Volume of the periodical
370
Issue of the periodical within the volume
únor
Country of publishing house
GB - UNITED KINGDOM
Number of pages
16
Pages from-to
191-206
UT code for WoS article
000422688200019
EID of the result in the Scopus database
2-s2.0-85024498625